Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.
- Published in:
- Current Medical Research & Opinion, 2025, v. 41, n. 5, p. 817, doi. 10.1080/03007995.2025.2497906
- By:
- Publication type:
- Article